Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer

Phillip J. Gray, David J. Bearss, Haiyong Han, Raymond B Nagle, Ming Sound Tsao, Nicholas Dean, Daniel D. Von Hoff

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Pancreas cancer is the fourth leading cause of cancer-related death in adults in the United States. New molecular targets for diagnosis and therapy of this disease are desperately needed. In this study, we report on the mitotic serine-threonine kinase polo-like kinase 1 (Pik1) in pancreatic cancer. Plk1 mRNA was found to be overexpressed in 9 of 10 tested pancreatic cancer cell lines and in 4 of 4 tested human tumors. Immunohistochemical staining of a pancreatic tissue microarray showed that 26 of the 35 tumors taken directly from patients overexpressed Plk1. We also examined the effects of depleting Plk1 in pancreatic cancer cells by the use of antisense oligonucleotides. Antisense-treated pancreatic cancer cells showed cell cycle arrest in G2-M as well as a drastic reduction in proliferation rates. These data suggest that Plk1 is a potential therapeutic target in devising a treatment for patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)641-646
Number of pages6
JournalMolecular Cancer Therapeutics
Volume3
Issue number5
StatePublished - May 2004

Fingerprint

Forensic Anthropology
Pancreatic Neoplasms
Therapeutics
G2 Phase Cell Cycle Checkpoints
Neoplasms
Antisense Oligonucleotides
Protein-Serine-Threonine Kinases
polo-like kinase 1
Staining and Labeling
Cell Line
Messenger RNA

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Gray, P. J., Bearss, D. J., Han, H., Nagle, R. B., Tsao, M. S., Dean, N., & Von Hoff, D. D. (2004). Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Molecular Cancer Therapeutics, 3(5), 641-646.

Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. / Gray, Phillip J.; Bearss, David J.; Han, Haiyong; Nagle, Raymond B; Tsao, Ming Sound; Dean, Nicholas; Von Hoff, Daniel D.

In: Molecular Cancer Therapeutics, Vol. 3, No. 5, 05.2004, p. 641-646.

Research output: Contribution to journalArticle

Gray, PJ, Bearss, DJ, Han, H, Nagle, RB, Tsao, MS, Dean, N & Von Hoff, DD 2004, 'Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer', Molecular Cancer Therapeutics, vol. 3, no. 5, pp. 641-646.
Gray, Phillip J. ; Bearss, David J. ; Han, Haiyong ; Nagle, Raymond B ; Tsao, Ming Sound ; Dean, Nicholas ; Von Hoff, Daniel D. / Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. In: Molecular Cancer Therapeutics. 2004 ; Vol. 3, No. 5. pp. 641-646.
@article{9d0afeef450e47e3a91f280971efffe2,
title = "Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer",
abstract = "Pancreas cancer is the fourth leading cause of cancer-related death in adults in the United States. New molecular targets for diagnosis and therapy of this disease are desperately needed. In this study, we report on the mitotic serine-threonine kinase polo-like kinase 1 (Pik1) in pancreatic cancer. Plk1 mRNA was found to be overexpressed in 9 of 10 tested pancreatic cancer cell lines and in 4 of 4 tested human tumors. Immunohistochemical staining of a pancreatic tissue microarray showed that 26 of the 35 tumors taken directly from patients overexpressed Plk1. We also examined the effects of depleting Plk1 in pancreatic cancer cells by the use of antisense oligonucleotides. Antisense-treated pancreatic cancer cells showed cell cycle arrest in G2-M as well as a drastic reduction in proliferation rates. These data suggest that Plk1 is a potential therapeutic target in devising a treatment for patients with pancreatic cancer.",
author = "Gray, {Phillip J.} and Bearss, {David J.} and Haiyong Han and Nagle, {Raymond B} and Tsao, {Ming Sound} and Nicholas Dean and {Von Hoff}, {Daniel D.}",
year = "2004",
month = "5",
language = "English (US)",
volume = "3",
pages = "641--646",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer

AU - Gray, Phillip J.

AU - Bearss, David J.

AU - Han, Haiyong

AU - Nagle, Raymond B

AU - Tsao, Ming Sound

AU - Dean, Nicholas

AU - Von Hoff, Daniel D.

PY - 2004/5

Y1 - 2004/5

N2 - Pancreas cancer is the fourth leading cause of cancer-related death in adults in the United States. New molecular targets for diagnosis and therapy of this disease are desperately needed. In this study, we report on the mitotic serine-threonine kinase polo-like kinase 1 (Pik1) in pancreatic cancer. Plk1 mRNA was found to be overexpressed in 9 of 10 tested pancreatic cancer cell lines and in 4 of 4 tested human tumors. Immunohistochemical staining of a pancreatic tissue microarray showed that 26 of the 35 tumors taken directly from patients overexpressed Plk1. We also examined the effects of depleting Plk1 in pancreatic cancer cells by the use of antisense oligonucleotides. Antisense-treated pancreatic cancer cells showed cell cycle arrest in G2-M as well as a drastic reduction in proliferation rates. These data suggest that Plk1 is a potential therapeutic target in devising a treatment for patients with pancreatic cancer.

AB - Pancreas cancer is the fourth leading cause of cancer-related death in adults in the United States. New molecular targets for diagnosis and therapy of this disease are desperately needed. In this study, we report on the mitotic serine-threonine kinase polo-like kinase 1 (Pik1) in pancreatic cancer. Plk1 mRNA was found to be overexpressed in 9 of 10 tested pancreatic cancer cell lines and in 4 of 4 tested human tumors. Immunohistochemical staining of a pancreatic tissue microarray showed that 26 of the 35 tumors taken directly from patients overexpressed Plk1. We also examined the effects of depleting Plk1 in pancreatic cancer cells by the use of antisense oligonucleotides. Antisense-treated pancreatic cancer cells showed cell cycle arrest in G2-M as well as a drastic reduction in proliferation rates. These data suggest that Plk1 is a potential therapeutic target in devising a treatment for patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=4444354564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444354564&partnerID=8YFLogxK

M3 - Article

C2 - 15141022

AN - SCOPUS:4444354564

VL - 3

SP - 641

EP - 646

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -